Higher hemoglobin levels and quality of life in patients with advanced chronic kidney disease: no longer a moving target?
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 27083270.
- Also identified by DOI 10.1016/j.kint.2016.03.001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
International clinical practice guidelines for the management of anemia in chronic kidney disease suggest target hemoglobin levels ≤ 11.5 g/dl (115 g/l), with individualized consideration of slightly higher hemoglobin targets to improve quality of life. An updated meta-analysis of randomized trials demonstrates no significant improvement in quality of life with erythropoietin-stimulating agent therapy targeting higher hemoglobin levels. Limitations of the available data suggest that individualized targets should nonetheless remain an option in future clinical practice guidelines.
Medical subject headings
- Erythropoietin
- Hematinics